Adicet Bio Inc ACET

Healthcare Biotechnology

Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

NDAQ:ACET - Post by User

Adicet Bio Inc

<< Previous

Bullboard Posts

Post by AviseAnalyticson Jan 24, 2022 7:27am

154 Views

Post# 34351368

7 REASONS TO PUT ADICET BIO ON YOUR WATCHLIST!

$ACET

Adicet Bio (NASDAQ: ACET) is a biotechnology Company working on bringing allogeneic gamma delta T cell therapies for cancer and other therapies. The Company announced positive interim clinical data from the first-ever allogenic, off-the-shelf, gamma delta CAR T Investigational therapy.

We take a look at the Company’s technology and pipeline.

Read on to know more!

https://www.aviseanalytics.com/7-reasons-to-put-adicet-bio-on-your-watchlist/

<< Previous

Bullboard Posts

The green resources stock scoring record quarterly growth